Results 41 to 50 of about 2,458 (200)

Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs:A practical and universal tool for management [PDF]

, 2022
Drug-drug interactions (DDIs) with anticancer drugs are common and can significantly affect efficacy and toxicity of treatment. Therefore, a Dutch Multidisciplinary Expert group is assessing the clinical signifi-cance of DDIs in oncology and provides ...
Jansman, Frank G A, Kwee, Wilma, le Comte, Marianne, Reyners, Anna K L, Steeghs, Neeltje, van den Tweel, Annemieke, van Gelder, Teun, van Leeuwen, Roelof W F, van Vlijmen, Bas, Visser, Otto, Wensveen, Brigit   +10 more
core   +3 more sources

Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia

Cancer Cell International, 2023
Background Acute myeloid leukaemia (AML) remains difficult to treat despite the development of novel formulations and targeted therapies. Activating mutations in the FLT3 gene are common among patients and make the tumour susceptible to FLT3 inhibitors ...
Jingmei Yang, Ran Friedman
doaj   +1 more source

A Highly Sensitive Nonextraction-Assisted HPLC Method with Fluorescence Detection for Quantification of Duvelisib in Plasma Samples and its Application to Pharmacokinetic Study in Rats

Drug Design, Development and Therapy, 2021
Ahmed Y Sayed, Nasr Y Khalil, Aliyah Almomen, Nourah Z Alzoman, Abdulrahman A Almehizia, Ibrahim A Darwish Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi ArabiaCorrespondence: Ibrahim A ...
Sayed AY, Khalil NY, Almomen A, Alzoman NZ, Almehizia AA, Darwish IA   +5 more
doaj  

High-Throughput/High Content Imaging Screen Identifies Novel Small Molecule Inhibitors and Immunoproteasomes as Therapeutic Targets for Chordoma

Pharmaceutics, 2023
Chordomas account for approximately 1–4% of all malignant bone tumors and 20% of primary tumors of the spinal column. It is a rare disease, with an incidence estimated to be approximately 1 per 1,000,000 people.
Amrendra K. Ajay, Philip Chu, Poojan Patel, Christa Deban, Chitran Roychowdhury, Radhika Heda, Ahmad Halawi, Anis Saad, Nour Younis, Hao Zhang, Xiuju Jiang, Mahmoud Nasr, Li-Li Hsiao, Gang Lin, Jamil R. Azzi   +14 more
doaj   +1 more source

DUO delivers for duvelisib [PDF]

Blood, 2018
In this issue of Blood, Flinn et al report the final results of the phase 3 registration trial DUO, which compared the novel PI3Kδ,γ inhibitor duvelisib with ofatumumab in patients with relapsed refractory chronic lymphocytic leukemia (CLL) and demonstrated a significant improvement in progression-free survival (PFS) with duvelisib.
openaire   +2 more sources

The TKI Era in Chronic Leukemias

Pharmaceutics, 2021
Tyrosine kinases are proteins involved in physiological cell functions including proliferation, differentiation, and survival. However, the dysregulation of tyrosine kinase pathways occurs in malignancy, including hematological leukemias such as chronic ...
Danilo De Novellis, Fabiana Cacace, Valeria Caprioli, William G. Wierda, Kris M. Mahadeo, Francesco Paolo Tambaro   +5 more
doaj   +1 more source

ANALYTICAL QUALITY BY DESIGN APPROACH IN RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF DUVELISIB [PDF]

, 2021
Objective: A simple, accurate, and robust RP-HPLC method was developed and validated for the estimation of Duvelisib using analytical quality by design approach.
CH, SRUJANI, KS, NATARAJ, MANJARI PAWAR A, KRISHNA, P, ANNAPURNA   +3 more
core   +1 more source

Controversies in the Treatment of Peripheral T-cell Lymphoma. [PDF]

, 2020
Peripheral T-cell lymphomas are a heterogeneous group of rare diseases with an aggressive behavior and dismal prognosis. Their classification is complex and still evolving, and several biomolecular markers now help refine the prognosis of specific ...
Bachy, E., Broccoli, A., de Leval, L., Dearden, C., Gaulard, P., Koch, R., Morschhauser, F., Trümper, L., Zinzani, P.L.   +8 more
core   +2 more sources

Dual inhibition of phosphoinositide 3-kinases delta and gamma reduces chronic B cell activation and autoantibody production in a mouse model of lupus

Frontiers in Immunology, 2023
Phosphoinositide 3-kinase delta (PI3Kδ) plays key roles in normal B cell activation and is chronically activated in malignant B cells. Targeting of PI3Kδ using FDA-approved drugs Idelalisib or Umbralisib has shown efficacy in treatment of multiple B cell
Folayemi Olayinka-Adefemi, Sen Hou, Aaron J. Marshall   +2 more
doaj   +1 more source

Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia [PDF]

Expert Opinion on Investigational Drugs, 2017
Introduction: Frontline chemotherapy is successful against chronic lymphocytic leukemia (CLL), but results in untoward toxicity. Further, prognostic factors, cytogenetic anomalies, and compensatory cellular signaling lead to therapy resistance or disease relapse. Therefore, for the past few years, development of targeted therapies is on the rise.
Hima V, Vangapandu, Nitin, Jain, Varsha, Gandhi   +2 more
openaire   +2 more sources